HTAs

Market Access

Industry exercises option for midpoint review of VPAG Invest...

Under the VPAG agreement, £400 million is available under the VPAG Investment Fund. But what benefits will stay once funding goes away in 2029?

Market Access

Health equity can be a competitive advantage: What pharma le...

As NICE begins to incorporate health equity into drug reimbursement decisions, forward-looking pharmaceutical companies have a chance to lead – aligning innovation with access drivers and g

Market Access

5 ways to address pricing and access challenges across the E...

In the feature ‘Successfully navigating the complexity of market access across Europe to improve health equity’, originally published in the European Biopharmaceutical Review, EVERSANA Gene

Market Access

NICE’s health inequalities modular update: A positive step, ...

The start of a new year saw the launch of a consultation on NICE’s eagerly anticipated health inequalities modular update to the manual for health technology evaluation.1

Market Access

Do better: The message to the industry from an analysis of c...

Dr Leeza Osipenko and colleagues analysed the quality of clinical evidence submitted by companies to NICE technology appraisals (TAs) over the last 20 years.

R&D

Modernising EU legislation: The Alliance for Regenerative Me...

Late last month, pharmaphorum met with Stephen Majors, global head of communications for the Alliance for Regenerative Medicine (ARM), to discuss the latest developments in the Advanced The

Industry exercises option for midpoint review of VPAG Invest...

Health equity can be a competitive advantage: What pharma le...

5 ways to address pricing and access challenges across the E...

NICE’s health inequalities modular update: A positive step, ...

Do better: The message to the industry from an analysis of c...

Modernising EU legislation: The Alliance for Regenerative Me...

uniQure sets course to US filing for Huntington gene therapy

Discover a new era of healthcare panel engagement: Grounded ...

HTAs

Editor's Picks